Liu Yang, Ph.D., M.D 

**Affiliations & Qualifications**  

• Joint-Training Ph.D. Candidate (CSC National Scholarship), Wuhan University/Harvard University (2018-2021) 

• Postdoctoral Fellow, Wuhan University (2021-2024)  

• Attending Physician & Associate Researcher, Second Clinical College of Wuhan University (2021-Present)  

**Editorial Roles**  

• Editorial Board/Youth Editorial Board Member:  

  *iMeta, Cell Proliferation, Exploration, Interdisciplinary Medicine, Responsive Materials, Nano TransMed*  

• Peer Reviewer:  

  *Chemical Engineering Journal, Experimental Hematology & Oncology, Free Radical Biology and Medicine* 

**Research Focus**  

Biomedical Materials | Cancer Immunotherapy | Nanozyme Applications  

**Publications & Grants**  

• Authored 20+ papers in high-impact journals (ACS Nano, Biomaterials, Journal of Nanobiotechnology, etc.) with cumulative impact factor >100  

• Principal Investigator of 7 national/provincial grants, securing >1 million CNY in research funding 

**Key Academic Contributions**  

1. Nanozyme-Enhanced Cancer Therapy 

   Developed a copper-doped dendritic mesoporous silica nanoparticle integrated with ceria-based nanozyme systems, achieving:  

   • Enhanced chemodynamic therapy (CDT) through tumor microenvironment-responsive catalytic reactions  

   • Synergistic photothermal effects for intraoperative hemostasis control  

   • Targeted suppression of tumor cell anoikis resistance, offering a dual-functional therapeutic strategy against post-surgical recurrence  

2. Wearable Artificial Kidney Innovation 

   Engineered self-assembled ordered zeolite materials featuring:  

   • High-efficiency toxin adsorption capacity (creatinine clearance rate: 92.4%)  

   • Cost-effective fabrication process compatible with flexible wearable devices  

   • Sustainable uremic toxin removal solution for next-generation renal replacement therapies